Aerovate Therapeutics, Inc. reported a significant reduction in operating expenses for the three months ended March 31, 2025, primarily due to the discontinuation of clinical operations and workforce reduction. The company incurred a net loss of $2.518 million, a substantial improvement from the $23.186 million net loss in the prior year. No revenue was generated, consistent with the company's current operational focus.

Aerovate Therapeutics reported a net loss of $23.2 million for the first quarter of 2024. The company's cash, cash equivalents, and short-term investments totaled $99.3 million as of March 31, 2024, which is expected to fund operations into 2026. Topline data from the Phase 2b portion of the IMPAHCT trial is expected in June 2024, and enrollment continues in the Phase 3 portion.

Aerovate Therapeutics reported cash, cash equivalents and short-term investments totaling $122.4 million as of December 31, 2023. The company's net loss for the year ended December 31, 2023, was $75.5 million. Topline data from the Phase 2b portion of the IMPAHCT trial is expected in June 2024.

Aerovate Therapeutics reported a net loss of $19.6 million for the third quarter of 2023, compared to a net loss of $13.6 million for the same period in 2022. Research and development expenses increased to $16.9 million, and general and administrative expenses rose to $4.5 million. The company's cash, cash equivalents, and available-for-sale securities totaled $135.2 million as of September 30, 2023, expected to fund operations into 2026.

Aerovate Therapeutics announced its Q2 2023 financial results, noting progress in its IMPAHCT Phase 2b/Phase 3 clinical trial and an extended cash runway into 2026. The company's cash, cash equivalents, and available-for-sale securities totaled $150.1 million. R&D expenses were $16.0 million, and G&A expenses were $4.3 million, resulting in a net loss of $19.0 million.

Aerovate Therapeutics announced its Q1 2023 financial results, highlighting progress on its IMPAHCT clinical trial with topline Phase 2b data expected in Q2 2024. The company's cash reserves are expected to fund operations into the second half of 2025.

Aerovate Therapeutics reported a net loss of $51.5 million for the year ended December 31, 2022. The company's cash, cash equivalents, and short-term investments totaled $129.2 million as of December 31, 2022, expected to fund operations into the second half of 2025.

Aerovate Therapeutics reported a net loss of $13.6 million for the third quarter ended September 30, 2022, compared to a net loss of $6.2 million for the third quarter ended September 30, 2021. Research and development expenses were $10.8 million, and general and administrative expenses were $3.4 million. Cash, cash equivalents, and short-term investments totaled $142.6 million as of September 30, 2022.

Aerovate Therapeutics reported a net loss of $12.0 million for the second quarter ended June 30, 2022, compared to a net loss of $5.8 million for the second quarter ended June 30, 2021. As of June 30, 2022, cash, cash equivalents and short-term investments totaled $152.0 million.

Aerovate Therapeutics reported a net loss of $10.9 million for the first quarter of 2022, driven by increased R&D and G&A expenses. The company's cash, cash equivalents, and short-term investments totaled $161.1 million as of March 31, 2022, expected to fund operations into the second half of 2025.

Aerovate Therapeutics reported its full-year 2021 financial results, highlighting the progress of its Phase 2b/Phase 3 trial of AV-101 in PAH and its financial position with $167.4 million in cash, cash equivalents, and short-term investments.

Aerovate Therapeutics reported a net loss of $6.2 million for the third quarter of 2021. The company's cash and cash equivalents totaled $180.9 million as of September 30, 2021, which they expect will be sufficient to fund operations into the second half of 2025.